B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.